Genzyme Corp. insists that investor Carl Icahn's interest in the company will not prompt a takeover. "To integrate us to into a very large entity is not that attractive. [The company] is much stronger as it is right now -- as a stand-alone rather than as part of a company 10 times our size," chief executive Henri Termeer said in an interview.

Related Summaries